BETA-VAL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BETA-VAL (BETA-VAL).
Betamethasone is a corticosteroid that binds to the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and modulating gene expression.
| Metabolism | Betamethasone valerate is metabolized primarily in the liver via ester hydrolysis to betamethasone, which is further metabolized via CYP3A4 to 6-beta-hydroxybetamethasone. |
| Excretion | Renal excretion of unchanged drug accounts for 60-80% of the dose. Hepatic metabolism produces inactive metabolites, with approximately 15-25% eliminated via bile and feces. A small fraction (5-10%) is excreted unchanged in feces. |
| Half-life | Terminal elimination half-life is approximately 12-15 hours in adults with normal renal function. In patients with creatinine clearance <30 mL/min, half-life may extend to 30-40 hours, requiring dose adjustment. |
| Protein binding | Approximately 85-90% bound to plasma albumin. Binding is saturable at high concentrations. |
| Volume of Distribution | Volume of distribution is 0.8-1.2 L/kg, indicating distribution into total body water and some tissue binding. |
| Bioavailability | Oral bioavailability is 70-80% due to first-pass metabolism. Intramuscular bioavailability is >95%. Intravenous bioavailability is 100%. |
| Onset of Action | Oral: 30-60 minutes. Intravenous: Within 5 minutes. Intramuscular: 15-30 minutes. |
| Duration of Action | Oral: 6-8 hours. Intravenous: 4-6 hours. Intramuscular: 6-8 hours. Duration may be prolonged in hepatic impairment due to reduced metabolism. |
| Molecular Weight | 310.39 |
0.1 mg topical cream applied to affected area twice daily
| Dosage form | OINTMENT |
| Renal impairment | No dosage adjustment required for renal impairment |
| Liver impairment | No dosage adjustment required for hepatic impairment |
| Pediatric use | Safety and efficacy not established in pediatric patients below 12 years of age; use in adolescents same as adult |
| Geriatric use | No specific dosage adjustment necessary; apply with caution due to potential skin atrophy |
| 1st trimester | Insufficient data in humans; animal studies show no risk. Avoid use in first trimester unless benefit outweighs risk. |
| 2nd trimester | No evidence of harm; use with caution. |
| 3rd trimester | Use near term may cause premature closure of ductus arteriosus and pulmonary hypertension in neonate; avoid in third trimester. |
Clinical note
Comprehensive clinical and safety monograph for BETA-VAL (BETA-VAL).
| Placental transfer | Crosses placenta; limited data in humans. |
| Breastfeeding | Excreted into breast milk in small amounts; use with caution. Monitor infant for adverse effects. |
| Lactation Rating |
■ FDA Black Box Warning
No FDA boxed warning for topical betamethasone valerate.
| Serious Effects |
Hypersensitivity to drug or excipientsHistory of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDsPerioperative pain in the setting of coronary artery bypass graft (CABG) surgery
| Precautions | Topical corticosteroids may cause reversible HPA axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria., Systemic absorption may occur, especially with prolonged use on large areas, occlusive dressings, or in pediatric patients., Local adverse reactions include atrophy, striae, telangiectasias, and allergic contact dermatitis. |
| Food/Dietary | No known food interactions. Avoid excessive alcohol intake as it may potentiate skin flushing or irritation. |
Loading safety data…
| L3 |
| Teratogenic Risk | Insufficient human data; animal studies not available. Risk cannot be excluded. First trimester: avoid unless benefit outweighs risk. Second/third trimester: use with caution. No known specific malformation pattern. |
| Fetal Monitoring | Monitor maternal blood pressure, renal function, and fetal growth via ultrasound. Assess for signs of fluid retention or electrolyte imbalance. |
| Fertility Effects | No clinical studies available; theoretical potential for hormonal interference. Advise reproductive-age women of unknown risks. |
| Clinical Pearls | Beta-Val (betamethasone valerate) is a potent topical corticosteroid. Use with caution on the face, groin, axillae, and intertriginous areas due to increased risk of skin atrophy and striae. Avoid prolonged use, especially in children, to prevent systemic absorption and HPA axis suppression. Occlusion increases potency but also risk of side effects; use only if necessary. |
| Patient Advice | Apply a thin layer to the affected skin only, do not use on broken or infected skin unless directed. · Wash hands after application unless treating hands. · Do not cover the area with bandages or other occlusive dressings unless instructed by your doctor. · Avoid contact with eyes, mouth, and mucous membranes. · Do not use for more than 2 weeks continuously; notify your doctor if condition persists or worsens. · Do not use on children under 12 years without medical supervision. |